IsoPlexis to Participate in Upcoming Investor Conferences
11/09/2022 - 07:00 AM
BRANFORD, Conn., Nov. 09, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be participating in the following investor conferences.
Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, New York, NY Multi-Omics Panel on Thursday, November 17th at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific Time Evercore ISI HealthCONx Conference, Virtual Fireside Chat on Thursday, December 1st at 12:10 p.m. Eastern Time / 9:10 a.m. Pacific Time A live webcast and replay of the Evercore ISI HealthCONx Conference fireside chat will be available on the “Investors” section of the company website at: www.isoplexis.com .
About IsoPlexis IsoPlexis is empowering labs to leverage the cells and proteome changing the course of human health. Its platforms provide insights into how multi-functional immune cells communicate and respond, assisting researchers in understanding and predicting disease progression, treatment resistance and therapeutic efficacy.
IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies by revenue and 78% of leading U.S. comprehensive cancer centers.
Investor Contact investors@isoplexis.com
Press Contact press@isoplexis.com
IsoPlexis Corp
NASDAQ:ISO
ISO Rankings
N/A Ranked by Stock Gains
ISO Stock Data
Industry
Testing Laboratories
Sector
Professional, Scientific, and Technical Services
About ISO
IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States and Europe. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations without the need for highly specialized informatics professionals, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.